Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VSTA will qualify for the bigger boards at that time. You don't get alot of chances to get a big board stock while they are still a pink, but this looks like it is one.
VSTA- This is a chart of beauty, higher highs and higher lows on a consistant basis.
VSTA just needs some volume here. It will have no problem moving once we see 2-5k volume. At least we know that there are no sellers here right now.
VSTA- With a backing from the NIH in the tune of $8.5 mil, you know there is confidenece.
VSTA-Strong backing:
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. To date, VSTA has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH).
VSTA-VSTA-It is also estimated that about one-third of all potential new drugs candidates fail in preclinical or clinical trials due to safety concerns. VSTA picks these up after other companies invest millions of dollars and years of research.
VSTA- With taht backing you know there will be success.
VSTA- The combination of VSTA’s proprietary and licensed technologies enables the development of 2D and 3D human cell-based bioassay systems that consist of large numbers of normal, non-transformed, human cells that function as “micro-organs”.
VSTA-Using mature human heart cells produced from pluripotent stem cells, They have leveraged their Human Clinical Trials in a TestTube™ platform to develop CardioSafe 3D™, a three-dimensional (3D) bioassay system for predicting the invivo cardiac effects of new drug candidates before they are tested in humans. VSTA plans to leverage CardioSafe 3D™ to build a pipeline of new, safer, drug rescue variants of promising drug candidates that have been “put on the shelf” by pharmaceutical companies because of toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.
VSTA-VSTA’s lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. To date, we have been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VSTA- And I love the part that they pick up projects that have had millions of dollars invested an years of time and works on getting them to approval. This is like money in the bank for VSTA!
VSTA- Near its high and been climbing for the past 2 months.
Current Price 3.0000
52 Week High 3.1000
VSTA- Been bullish for some time and no shares being sold. Time to acculmulate
Period Moving Average Price Change Percent Change Average Volume
5-Day 3.0300 +0.1000 +3.45% 960
20-Day 2.8085 +0.3100 +11.52% 820
50-Day 2.5916 +0.4400 +17.19% 1,032
VSTA-
Period Moving Average
Price Change Percent Change Average Volume
5-Day 3.0300 +0.1000 +3.45% 960
20-Day 2.8085 +0.3100 +11.52% 820
50-Day 2.5916 +0.4400 +17.19% 1,032
VSTA- Playing it smart with other companies money, then cashing in.
VSTA is involved with Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (drug rescue variants) of promising drug candidates that have been discontinued during preclinical development (put on the shelf) due to heart or liver safety concerns.
VSTA is involved with Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (drug rescue variants) of promising drug candidates that have been discontinued during preclinical development (put on the shelf) due to heart or liver safety concerns.
VSTA- I was just looking at that and expect to see some volume at anytime now. We know there is no selling going on.
VSTA-Our drug rescue model is designed to leverage both the pharmaceutical company's prior investment in preclinical development of promising drug candidates put on the shelf and the predictive toxicology and drug development capabilities of our Human Clinical Trials in a Test Tube tm platform
VSTA-Our drug rescue model is designed to leverage both the pharmaceutical company's prior investment in preclinical development of promising drug candidates put on the shelf and the predictive toxicology and drug development capabilities of our Human Clinical Trials in a Test Tube tm platform."
VSTA-
Corporate Objective Per 10Q:
"We are a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. Drug rescue involves the combination of human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity. We anticipate that our stem cell technology platform, Human Clinical Trials in a Test Tube, will allow us to assess the heart and liver toxicity profile of new drug candidates with greater speed and precision than nonclinical in vitro techniques and technologies currently used in the drug development process. Our drug rescue model is designed to leverage both the pharmaceutical company's prior investment in preclinical development of promising drug candidates put on the shelf and the predictive toxicology and drug development capabilities of our Human Clinical Trials in a Test Tube tm platform."
VSTA-Corporate Objective Per 10Q:
"We are a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. Drug rescue involves the combination of human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity. We anticipate that our stem cell technology platform, Human Clinical Trials in a Test Tube, will allow us to assess the heart and liver toxicity profile of new drug candidates with greater speed and precision than nonclinical in vitro techniques and technologies currently used in the drug development process. Our drug rescue model is designed to leverage both the pharmaceutical company's prior investment in preclinical development of promising drug candidates put on the shelf and the predictive toxicology and drug development capabilities of our Human Clinical Trials in a Test Tube tm platform."
VSTA That they are, and fully reporting, nothing to hide.
VSTA- I confirmed that today myself, that is awesome
VSTA- The plan seems to be a good idea, take someone's early work and progress and turn it into VSTA's revenues and profits.
VSTA-VistaGen is also developing LiverSafe 3D™, a predictive liver toxicity and drug metabolism bioassay system, and is preparing to initiate pilot preclinical development of cell therapy programs focused on autologous bone marrow transplantation and heart, liver and cartilage repair. Each of these development programs is based on the proprietary human pluripotent stem cell differentiation and cell production capabilities of the Company's Human Clinical Trials in a Test Tube™ platform.
VSTA-VistaGen is also developing LiverSafe 3D™, a predictive liver toxicity and drug metabolism bioassay system, and is preparing to initiate pilot preclinical development of cell therapy programs focused on autologous bone marrow transplantation and heart, liver and cartilage repair. Each of these development programs is based on the proprietary human pluripotent stem cell differentiation and cell production capabilities of the Company's Human Clinical Trials in a Test Tube™ platform.
VSTA- Part of VSTA's Management:
Shawn Singh, J.D.
Chief Executive Officer, Director
Mr. Singh has over 20 years of experience working with public and private biotechnology and pharmaceutical companies,
serving in numerous senior management roles. He served as Managing Principal of Cato BioVentures, a biopharmaceutical
venture capital firm, as Chief Business Officer of Cato Research Ltd., a global contract research and development
organization (CRO), as President of Echo Therapeutics (Nasdaq: ECTE), a medical device company targeting diabetes
management, and as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a revenue-producing specialty
pharmaceutical company focused on cancer and infectious disease. Mr. Singh began his career as a corporate finance
attorney in the Silicon Valley offices of Morrison & Foerster LLP. Mr. Singh is a member of the State Bar of California.
VSTA-
VistaGen's website www.VistaGen.com
VSTA- This is a real rewarding field and when they do have approvals, the growth will be expodential.
VSTA- Has gone from $1.88 to $3.10 in 2 months and volume is starting to pick up. Could be $4.00 in a short time with all they have going on. Medical companies are bullet proof these days.
VSTA- Radar this one, it is ready to move toward OTC from what I see.
VistaGen Therapeutics, Inc. is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (drug rescue variants) of promising drug candidates that have been discontinued during preclinical development (put on the shelf) due to heart or liver safety concerns. We also focus on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VSTA: The potential is huge here, that is an understatement. Once one of these product makes it through the process, we are looking at another Pzizer story.
SATM-Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% Buy
20-Day Average Volume - 382,609
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% Buy
50-Day Average Volume - 189,172
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
SATM-Momentum Indicators
10 Day Trend bullish
40 Day Trend bullish
SATM-
GESI Targets $15 Million Annual Green Energy Project With Alberta Energy and On-Track Technologies
Date : 10/11/2011 @ 9:45AM
Source : MarketWire
Stock : Green Energy Solution Industries, Inc.; SatMAX Corp. (SATM)
SATM-GESI Targets $15 Million Annual Green Energy Project With Alberta Energy and On-Track Technologies
Date : 10/11/2011 @ 9:45AM
Source : MarketWire
Stock : Green Energy Solution Industries, Inc.; SatMAX Corp. (SATM)
SATM-Satmax Corp (PN) (SATM)
0.043 + 0.0031 (7.77%)
Volume: 4,852,078
SATM- Economic Value of Wood Waste
In the past few years we have seen the Wood Waste Energy Sector grow at an unprecedented pace due to numerous factors:
• Reduce greenhouse gas emissions
• Reduce the amount of toxic pollutants in the atmosphere
• Save landfill space from taking up more of our landscape and Reduce groundwater
contaminants
• Improve energy security and reduce dependence on foreign sources of energy
Wood fuels can be cheaper than coal (dollars per Btu), and always emit less air pollution.
In cases where cost of disposal is avoided, wood waste may even have a negative price.
Energy projects using the abundant wood waste found on many federal lands can not only displace the use of fossil fuels but also reduce the risk of forest fires.
Recently SATM has been awarded a grant by the Canadian government:
SATM- Economic Value of Wood Waste
In the past few years we have seen the Wood Waste Energy Sector grow at an unprecedented pace due to numerous factors:
• Reduce greenhouse gas emissions
• Reduce the amount of toxic pollutants in the atmosphere
• Save landfill space from taking up more of our landscape and Reduce groundwater
contaminants
• Improve energy security and reduce dependence on foreign sources of energy
Wood fuels can be cheaper than coal (dollars per Btu), and always emit less air pollution.
In cases where cost of disposal is avoided, wood waste may even have a negative price.
Energy projects using the abundant wood waste found on many federal lands can not only displace the use of fossil fuels but also reduce the risk of forest fires.
Recently SATM has been awarded a grant by the Canadian government:
SATM-SATM announced that it has reached an agreement with On-Track Railway Services, Ltd. of Edmonton Canada, a major servicer in the rail industry throughout Western Canada, for a large scale supply of railway ties to be used as feedstock for SATM’s waste wood to energy project in the Industrial Heartland of Alberta.
On-Track processes millions of used ties per year from major and other rail sources.
The agreement with On-Track is for a minimum of 300,000 rail ties per year (30,000 tons) up to 1,500,000 rail ties per year to be supplied to SATM at no cost for use as feedstock for conversion from waste wood to energy.